ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

vadadustat

Also written as “Vadadustat”, “AKB-6548” and “MT-6548”.

Its studies are mostly in Anemia · Renal Insufficiency, Chronic, led by 2 companies.

Drug pageVadadustat: every studyAll 40 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Jan 4, 201636 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Akebia Therapeuticsits history only320 open or runningphase 3since Jan 4, 2016Nov 5, 2010none ahead
Tanabe Pharma40 open or runningphase 3since Oct 30, 2017Oct 30, 2017none ahead

Also a collaborator on its studies: Otsuka.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Tanabe Pharma only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Dec 9, 2015Named vadadustatINNProposed as its International Nonproprietary Name in WHO's List 114 · before, AKB-6548, MT-6548
  2. Oct 30, 2017First study: phase 3 study in AnemiaFirst studyNCT03329196 · 304 enrolled · Japan
  3. Dec 27, 2017Phase 3 study in AnemiaNCT03402386 · 42 enrolled · Japan
  4. Feb 14, 2018Phase 3 study in AnemiaNCT03439137 · 323 enrolled · Japan
  5. Mar 5, 2018Phase 3 study in AnemiaNCT03461146 · 24 enrolled · Japan

TargetBeta

“Egl nine homolog 1 inhibitor; Egl nine homolog 3 inhibitor; Hypoxia-inducible factor prolyl hydroxylase 1 inhibitor”ChEMBL 37, by rule

Other programs on the same three targets

ProgramCompanyFurthest phaseStudies
roxadustatruleAstellas Pharmaphase 447
daprodustatruleGlaxoSmithKlinephase 333

Studies

All 4 Tanabe Pharma leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03461146Anemia · Japan3CompletedDec 3, 201824
NCT03439137Anemia · Japan3CompletedDec 12, 2018323
NCT03402386Anemia · Japan3CompletedNov 22, 201842
NCT03329196Anemia · Japan3CompletedJan 8, 2019304

How it is read

Names in the registry

  • “Vadadustat”, 19 entries
  • “AKB-6548”, 8 entries
  • “MT-6548”, 4 entries
  • “vadadustat”, 4 entries
  • “vadadustat reference tablets”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.